Navigation Links
Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor

LONDON, April 4, 2007--Treatment data from Synovate Healthcare’s European Oncology Monitor reveals that over 10,000 breast cancer patients in the UK could become eligible for a breast cancer treatment showing lower death rates in patients. The treatment was the subject of a recent study detailed in the online edition of The Lancet (12 February 2007). Lower mortality rates were shown in patients who had switched to the aromotase inhibitor, Aromasin (exemestane), after 2-3 years of the current standard hormone drug therapy, tamoxifen. Aromasin was recently approved by the National Institute for Clinical Excellence (NICE).

Patients who could be eligible in this new indication were defined as newly diagnosed women in early stage disease who test positive for markers indicating hormone therapy as a treatment option, as well as those who have been on tamoxifen for 3 years or less. According to Synovate Healthcare’s data, 80% of drug-treated patients diagnosed in early stages are hormone responsive. Types of hormone therapies include tamoxifen and three aromatase inhibitors recently approved by the NICE. About 13% of newly diagnosed early stage breast cancer patients receive tamoxifen therapy in the UK annually.

Cancer Research UK and Globocan statistics from the World Health Organisation suggest that over 40,000 cases of breast cancer are diagnosed in the UK each year. Synovate Healthcare data shows that over 23,000 newly diagnosed patients are treated with drug therapies. Using data on the number of newly diagnosed women in early stage disease, together with the number of existing patients on tamoxifen, Synovate Healthcare estimates that over 10,000 breast cancer patients in the UK could become eligible for this new treatment within the next year.

Leah Krukowski, Head of Synovate Healthcare’s European Oncology Monitor, commented, “It is encouraging to see how many peoples&
'"/>




Page: 1 2 3

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
4. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
5. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
6. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
7. Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds
8. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
9. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
10. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014  Decision Resources Group finds that the ... around $7.7 billion by 2023 in the United ... Germany , Italy , ... and Japan . The biosimilar erosion of ... balanced out by the launch of Eli Lilly,s Cyramza, Taiho ...
(Date:8/28/2014)... 2014 Levi & Korsinsky announces that a ... States District Court for the District of ... Galectin Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt ... Class Period the Company violated federal securities laws by ...
(Date:8/28/2014)... Nonin Medical, Inc., the inventor of finger pulse oximetry ... that the Food and Drug Administration (FDA) has cleared ... use in the United States . ... or kiosk through a USB connector and measures oxygen ... The Model 3231 received EU certification last year. ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... 15, 2012 Senior representatives from leading pharmaceutical ... Novartis MIT will meet at the Pharma Qbd Forum in ... to share their expert knowledge on how Quality by Design ... the main points of discussion will be the findings of ...
... Feb. 14, 2012  At a meeting held today, the Directors ... per share. The dividend is payable on March 15, 2012 ... About Sigma-Aldrich :  Sigma-Aldrich ... High Technology company whose biochemical, organic ...
Cached Medicine Technology:Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono 2
(Date:8/28/2014)... To kick off the fall season of sporting ... retailers across the country are offering 0% financing for ... Tub Tailgate Event is from August 29th-September 15th. ... and to apply early! , As the leader in ... of outdoor hot tubs with exclusive features at your ...
(Date:8/28/2014)... repairing nerves with adhesives, most researchers place glue directly ... fix the nerve ends well and allows glue to ... cylindrical. However, it is difficult to insert the nerve ... and there is frictional resistance. Xiangdang Liang and co-workers ... special conduit for the adhesive technique and defined the ...
(Date:8/28/2014)... 2014 One in every 200 Ontarians has been ... of people living with the disease increasing by 64 ... study by researchers at the Institute for Clinical Evaluative ... and the Ottawa Hospital Research Institute. That puts Ontario ... world. , The study, published this week in ...
(Date:8/28/2014)... 28, 2014 BCC Research ( http://www.bccresearch.com ... SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , the global market ... in 2013. Driven by the need for replacement of ... in emerging geographies, the market is expected to grow ... (CAGR) of 8.5% from 2013 through 2018. , While ...
(Date:8/28/2014)... Parker Waichman LLP, a national personal ... to ensure that the heroes of 9/11 are never ... WTC victims who developed 9/11-related cancer was reaffirmed by ... (GAO). According to a statement issued by 9/11 ... entitled “World Trade Center Health Program: Approach Used to ...
Breaking Medicine News(10 mins):Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3
... ORLEANS, Sept. 28 Sanarus Medical today announced ... centers across,the country. These Centers, including breast care ... with Sanarus to,increase the awareness and availability of ... breast tumors, known as,fibroadenomas. Sanarus will host a ...
... Sept. 28 Today, at the Clinton,Global Initiative, ... total value is $1,000,000. Fulvio,Renoldi Bracco, Bracco AMT,s ... company and said that the partnership would provide ... Heart Hospital, in,Changchun City, Jilin Province, China -- ...
... N.J., Sept. 28 Whether she is giving a,keynote ... Esther Paik Goodhart conveys optimism and possibility. "Only ... I have,",says Goodhart with a warm laugh, "I,m a ... I teach Hebrew at three temples,and I,m running for ...
... Inc. ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer ... be unable to file its Annual Report on,Form 10-K ... a timely basis because,it requires additional time to complete ... Annual Report on Form 10-K no later than,October 15, ...
... 28 Amid increasing pressure to combat,childhood obesity, the ... eleven-year-olds will lumber forward, breaking the $1,billion mark in ... the,U.S., a new report from market research publisher Packaged ... of kids, licensed food and,beverage products rose 9%, from ...
... University of Kentucky Center for Poverty Research has received ... Association of America Foundation (MOWAAF) to study the economic ... in America. , James Ziliak, Gatton Endowed Chair of ... at UK, part of the Gatton College of Business ...
Cached Medicine News:Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2Health News:Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI 2Health News:Humor and Hope Sustain NJ Woman Through Disabling Movement Disorder, Election Campaign 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 3Health News:Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids' Licensed Foods and Beverages 2Health News:Center for Poverty Research to study senior hunger in America 2
... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
Medicine Products: